Answers are grounded in this paper and cite their sources.
Cohort study reveals HIRA loss occurs in 73.9% of human FH-deficient renal tumors, indicating distinct MYC/mTORC1 versus Wnt/Notch oncogenic trajectories.
Fumarate hydratase-deficient renal cell carcinoma (FH-dRCC) is a rare and highly aggressive malignancy driven by fumarate accumulation and widespread epigenetic reprogramming. Although Valcarcel-Jimenez et al. have demonstrated that loss of the histone chaperone Hira is a critical and necessary event for the malignant transformation of Fh1 -deficient cells through activation of MYC-dependent transcriptional programs based on murine models, by analyzing HIRA protein expression and transcriptomic profiles in a multicenter cohort of human FH-dRCC tumors harboring either germline or somatic FH mutations, we found that HIRA loss was frequent (73.9%, 17/23) but not universal. Although HIRA status was not associated with clinical outcomes, transcriptomic analyses revealed two divergent oncogenic programs: HIRA-negative tumors are characterized by activation of MYC and mTORC1 signaling, whereas HIRA-positive tumors preferentially engage Wnt and Notch pathways. These findings suggest that HIRA loss is not an obligate event in human FH-dRCC tumorigenesis, but instead may direct toward distinct molecular trajectories.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: